SEC Form 4 · accession 0000921895-26-002203
Starling Oncology, Inc. · STLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jorey Chernett
10% Owner
Period of report
Aug 13, 2026
Accepted (ET)
Aug 17, 2026 · 10:13 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001799191
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 14, 2026 | P | 12,000 | $6.54 | A | 10,660,858 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Call Option (STLN 19FEB27 $9C)F1 | $9.00 | Aug 13, 2026 | S | 100 | D | Aug 13, 2026 | Feb 19, 2027 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.